The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients

Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients. In this pilot study, we assessed with the ELISA method...

Descripción completa

Detalles Bibliográficos
Autores principales: Wencel-Warot, Agnieszka, Michalak, Slawomir, Warot, Marcin, Kalinowska-Lyszczarz, Alicja, Kazmierski, Radoslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106061/
https://www.ncbi.nlm.nih.gov/pubmed/27828855
http://dx.doi.org/10.1097/MD.0000000000005337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106061/
https://www.ncbi.nlm.nih.gov/pubmed/27828855
http://dx.doi.org/10.1097/MD.0000000000005337

Ejemplares similares